Experience and BCC subtypes as determinants of MAL-PDT response: preliminary results of a national Brazilian project by Ramirez, Dora P. et al.
  Universidade de São Paulo
 
2014-03
 
Experience and BCC subtypes as
determinants of MAL-PDT response:
preliminary results of a national Brazilian
project
 
 
Photodiagnosis and Photodynamic Therapy, Amsterdam : Elsevier BV, v. 11, n. 1, p. 22-26, Mar.
2014
http://www.producao.usp.br/handle/BDPI/50835
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Física e Ciências Materiais - IFSC/FCM Artigos e Materiais de Revistas Científicas - IFSC/FCM
Photodiagnosis and Photodynamic Therapy (2014) 11, 22—26
Available  online  at  www.sciencedirect.com
ScienceDirect
jo ur nal ho mepage: www.elsev ier .com/ locate /pdpdt
Experience  and  BCC  subtypes  as
determinants of  MAL-PDT  response:
Preliminary results  of  a  national  Brazilian
project
Dora  P.  Ramirez  MD,  MSca,∗,  Cristina  Kurachia,
Natalia  M.  Inadaa,  Lilian  T.  Moriyamaa,  Ana  G.  Salviob,
José D.  Vollet  Filhoa,  Layla  Piresa,  Hilde  H.  Buzzáa,
Cintia  Teles  de  Andradea,  Clovis  Grecoa,  Vanderlei  S.  Bagnatoa
a Biophotonics  Laboratory,  São  Carlos  Institute  of  Physics,  University  of  São  Paulo  (USP),  13566-590  São
Carlos, São  Paulo,  Brazil
b Skin  Department,  Amaral  Carvalho  Foundation,  Brazil
Available  online  8  January  2014
KEYWORDS
Non-melanoma  skin
cancer;
Photodynamic
therapy;
National  Brazilian
project;
BCC subtypes;
Doctor  experience;
Determinants
Summary  Non-melanoma  skin  cancer  is  the  most  prevalent  cancer  type  in  Brazil  and  world-
wide.  Photodynamic  therapy  (PDT)  is  a  noninvasive  technique  with  excellent  cosmetic  outcome
and  good  curative  results,  when  used  for  the  initial  stages  of  skin  cancer.  A  Brazilian  program
was  established  to  determine  the  efﬁcacy  of  methyl  aminolevulinate  (MAL)-PDT,  using  Brazilian
device  and  drug.  The  equipment  is  a  dual  device  that  combines  the  photodiagnosis,  based  on
wideﬁeld  ﬂuorescence,  and  the  treatment  at  630  nm.  A  protocol  was  deﬁned  for  the  treatment
of  basal  cell  carcinoma  with  20%  MAL  cream  application.  The  program  also  involves  the  training
of  the  medical  teams  at  different  Brazilian  regions,  and  with  distinct  facilities  and  previous
PDT  education.  In  this  report  we  present  the  partial  results  of  27  centers  with  366  treated  BCC
lesions  in  294  patients.  A  complete  response  (CR)  was  observed  in  76.5%  (280/366).  The  better
response  was  observed  for  superﬁcial  BCC,  with  CR  160  lesions  (80.4%),  when  compared  with
nodular  or  pigmented  BCC.  Experienced  centers  presented  CR  of  85.8%  and  90.6%  for  superﬁ-
cial  and  nodular  BCC  respectively.  A  high  inﬂuence  of  the  previous  doctor  experience  on  the  CR
values  was  observed,  especially  due  to  a  better  tumor  selection.
© 2013  Elsevier  B.V.  All  rights  reserved.
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Introduction
The  non-melanoma  skin  cancer  (NMSC)  represents  the  most
common type  of  cancer  worldwide.  In  the  United  States,
it accounts  for  more  than  2  million  cases  per  year  and,
in Brazil,  more  than  130,000  new  cases  were  estimated
1572-1000/$ — see front matter © 2013 Elsevier B.V. All rights reserved.
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for  2012,  with  the  basal  cell  carcinoma  (BCC)  representing
approximately  to  80%  of  all  NMSC  lesions  [1].
PDT  has  been  investigated  for  several  applications,  being
widely  used  for  the  treatment  of  NMSC  [2,3].  Three  elements
are  fundamental  in  PDT:  the  presence  of  a  photosensitizer
(PS),  a  molecule  which  absorbs  light  to  initiate  a  series  of
photochemical  reactions;  light  at  a  speciﬁc  wavelength  to
be  absorbed  by  the  PS;  and  the  availability  of  molecular
oxygen  in  the  tissue  to  be  treated  [3,4].  The  combina-
tion  of  drug,  light  and  oxygen  leads  to  the  production  of
oxidative  cytotoxic  agents,  leading  the  treated  tissue  to
death  by  inducing  necrosis,  apoptosis  or  autophagy,  when
a  irreversible  damage  is  achieved  [4].  Methyl  aminolevuli-
nate  (MAL)  is  topically  administered  to  the  patient,  using
a  transdermal  delivery  cream.  MAL  penetrates  in  the  cells
and  the  aminolevulinic  acid  induces  in  the  mitochondria,  the
protoporphyrin  IX  (PpIX)  production  [4].
For  a  decade,  our  group  has  been  introducing  PDT  as  an
experimental  therapeutic  option  in  Brazil  [5].  After  several
years  of  local  experience,  we  have  organized  a  national  ini-
tiative  with  the  main  goal  of  installing  about  100  centers
and  treatment  of  approximately  2000  lesions  to  evaluate
the  efﬁcacy  of  the  proposed  protocol  and  a  new  device  that
combines  the  ﬂuorescence  visualization  and  treatment.
The  low  accessibility  to  imported  drug  and  equipment,
mainly  due  to  the  high  costs,  prevents  a  large  clinical  imple-
mentation  of  PDT  among  Brazilian  dermatologists.  Brazil  is
a  country  with  a  large  territorial  area;  the  patient  access  to
specialized  facilities  is  difﬁcult  and  inefﬁcient  considering
the  long  distances  and  waiting  list,  which  in  some  regions
can  achieve  12  months.
With  the  disponibility  of  Brazilian  drug  and  equipment,
the  costs  of  a  PDT  procedure  decrease  signiﬁcantly,  allowing
a  high  technique  implementation.  First  of  all,  these  com-
ponents  must  be  tested  before  its  disponibilization  by  the
public  health  system.  This  program  has  as  a  major  aim  to
evaluate  all  these  at  different  medical  levels,  from  sim-
ple  general  facility  to  highly  qualiﬁed  cancer  centers,  and
Brazilian  regions.  For  the  validity  of  the  program,  as  well
as  to  promote  adjustments  that  guarantees  a  full  success,
it  is  necessary  the  analysis  of  different  response  aspects.
Therefore  in  this  communication,  we  present  some  aspects
concerning  the  PDT  clinical  outcome  based  on  partial  results
(with  about  20%  of  the  expected  number  of  patients)  already
collected.  The  complete  response  depending  on  a  previous
professional  experience  and  the  BCC  subtypes  is  presented.
Materials and methods
Training  the  centers
This  is  a  multicenter  prospective  study  involving  27  der-
matological  centers  in  Brazil.  Each  center  was  classiﬁed  as
experienced  (EC)  or  not  experienced  center  (NEC)  according
to  the  spontaneous  physicians  report,  regarding  their  own
previous  knowledge  and/or  practice  with  PDT  for  more  than
one  year.
Regardless  of  this  experience,  all  teams  received  the
same  training,  lasting  8  h,  which  included  a  lecture  with
the  concepts  of  photodynamic  therapy,  pharmacology  and
all  clinical  protocol  followed  by  training  with  practical
application  of  the  protocol  in  patients  previously  sched-
uled.  A  training  team  was  composed  of  doctors,  pharmacists,
physicists  and  related  ﬁelds  toward  a  more  comprehensive
approach  to  the  concepts  involved.
The  presented  data  are  from  14  EC  and  13  NCE.  The  study
was  approved  by  local  Internal  Review  Board,  and  by  the
Brazilian  Federal  Council  on  Ethics.  All  patients  provided  a
written  informed  consent  before  enrollment  into  the  study.
Clinical  protocol
Eligible  patients  were  subjects  of  both  genders,  over  18
years  old  with  primary  superﬁcial  (sBCC),  nodular  (nBCC)
and  pigmented  (pBCC)  BCC  with  diameter  less  than  of
20  mm,  estimated  clinically  immediately  prior  to  treatment.
The  maximum  thickness  of  the  tumor  was  2  mm.  This  eval-
uation  was  done  for  histopathological  or  clinical  analysis.
Pregnant  women  and  subjects  presenting  porphyria  or  any
type  of  photosensitivity  were  excluded.
All  lesions  were  measured  and  photographed.  Then,
the  lesion  was  investigated  using  the  ﬂuorescence  visor
—  (LINCE®, MMOptics,  Brazil)  that  emits  an  ultraviolet-
blue  light  centered  at  400  ±  10  nm,  from  an  LED  array  and
with  irradiance  of  40  ±  8  mW/cm2. Autoﬂuorescence  visu-
alization  improves  the  physician  ability  on  discrimination
of  altered  tissues,  by  highlighting  lesion  structures.  Super-
ﬁcial  BCC  lesions  were  prepared  by  surface  debridement
to  remove  scales  and  crusts  and  to  facilitate  penetra-
tion  of  the  MAL  cream.  For  nBCC,  a  curettage  without
local  anesthesia  was  performed  to  reduce  the  tumor  thick-
ness,  resulting  in  a ﬂat  surface.  Was  used  MAL  200  mg/g
cream  containing:  methylparaben,  propylene  glycol,  EDTA
(ethylenediaminetetraacetic  acid),  DMSO  (dimethyl  sulfox-
ide),  BHT  (butylated  hydroxytoluene),  imidazolidinyl  urea,
water,  Polawax,  decila  oleate,  Nipasol  (PDT-Pharma,  Crav-
inhos,  SP,  Brazil)  was  placed  over  the  lesion,  including
an  extension  to  5  mm  of  normal  surrounding  skin,  with  at
least  1  mm  thickness.  An  occlusive  dressing,  using  plas-
tic  ﬁlm  and  aluminum  foil  was  placed  for  3  h.  After  that,
the  dressing  was  removed,  the  cream  was  washed  off  with
saline  solution.  The  presence  of  PpIX,  a  highly  ﬂuorescent
molecule,  was  veriﬁed  by  using  the  ﬂuorescence  visor  to
observe  the  characteristic  red  ﬂuorescence  under  405  nm
excitation.  The  uniformity  and  intensity  of  the  red  ﬂuores-
cence  give  indication  to  evaluate  the  PpIX  production.  If
there  is  lack  or  dimmed  red  emission,  the  photodynamic
response  will  not  take  place.  If  there  is  a  non-uniform
PpIX  distribution,  the  PDT  will  not  properly  occur,  poten-
tially  resulting  in  remaining  untreated  cancer  cells.  After
checking  the  PpIX,  the  lesion  was  immediately  illuminated
with  a  red  (630  ±  10  nm)  LED  light  source  (LINCE®, MMOp-
tics,  Brazil),  with  irradiance  of  125  mW/cm2,  and  ﬂuence  of
150  J/cm2.  Subsequently  to  treatment,  PpIX  photobleaching
was  veriﬁed  by  ﬂuorescence  imaging  in  order  to  evaluate
consumption  of  PS  and  certiﬁcation  of  an  expected  photo-
dynamic  reaction.  We  believe  that  a ﬂuorescence  visor  is  a
relevant  device  to  enable  an  improved  lesion  examination,
and  analysis  of  the  PDT  steps,  giving  clinical  information  to
predict  the  individual  response.
The  same  protocol  was  repeated,  with  an  interval  of  1
week  between  sessions.
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Table  1  Clinical  characteristics  of  the  patients  and  lesion.
Clinical  characteristics  Number  or  percent
Male/female  144/222  lesions
Lesion  location,  no.  (%)
Head  and  neck  80.8%
Upper and  lower  extremities  6.5%
Trunk 12.5%
Histological  subtypes
Superﬁcial  BCC  199  lesions
Nodular  BCC 151  lesions
Pigmented  BCC 16  lesions
Evaluation  of  response
Thirty  days  after  the  second  PDT  session,  the  patient  was
clinically  evaluated  by  the  physicians  with  digital  pictures  to
help  the  macroscopic  analysis  and  a  punch  biopsy  was  per-
formed  for  histological  analysis.  The  ﬁnal  response,  based
on  the  clinical  and  histological  analyses,  was  classiﬁed  as
complete  response  (CR),  partial  response  (PR)  or  interrupted
treatment  (IT).
CR  was  used  to  classify  results  when  no  lesion  was
observed  in  clinical  and/or  histological  analysis.  PR  was  used
for  lesions  that  have  regressed,  but  not  enough  to  eradicate
the  lesion.  IT  was  used  when  there  were  external  causes  for
the  patient.  There  was  no  reported  allergic  reaction.
Statistical  analysis
Statistically,  data  were  reported  as  numbers  and/or  per-
centages.  The  chi-square  statistic  was  used  to  assess
predetermined  bivariate  comparisons,  and  the  equal  pro-
portions  hypothesis  was  rejected  when  the  P  values  were
less  than  0.05.
Results
In  this  multicenter  study,  294  patients  with  a  total  of  366
BCC  lesions  were  treated  in  27  different  centers.  The  skin
type,  I—VI  rated  according  to  the  Fitzpatrick’s  classiﬁca-
tion,  of  each  patient  was  recorded.  From  all  lesions,  296
(80.8%)  were  located  at  the  head  and  neck,  24  (6.5%)  at
upper  and  lower  extremities,  and  46  (12.5%)  at  the  trunk.
Two  hundred  and  twenty-two  lesions  (60.6%)  were  diagnosed
in  women,  and  144  lesions  (39.3%)  in  men.  CR  was  observed
in  76.5%  (280/366),  PR  in  20.2%  (74/366),  IT  in  3.2%  (12/366)
of  the  cases  (Table  1).  The  better  response  was  observed  for
sBCC,  with  160  CR  (80.4%),  29  PR  (14.5%),  and  10  IT  (5%)
of  treated  lesions  (P  <  0.01).  For  nBCC,  the  results  were:  CR
at  112  lesions  (74.1%),  PR  at  37  (24.5%),  and  IT  at  2  (1.3%)
(P  <  0.01).  Only  16  pBCC  lesions  were  included  in  the  present
study,  showing  CR  at  50%,  and  PR  at  50%  of  the  cases  (Fig.  1).
In  Fig.  2,  a  comparison  between  the  results  obtained  at  expe-
rienced  centers  (EC)  and  non-experienced  centers  (NEC)  is
presented.  EC  corresponds  to  centers  where  the  profession-
als  self-related  previous  experience  in  PDT,  while  NECs  are
those  introduced  to  PDT.  There  is  an  evident  higher  CR  rates
Figure  1  Response  of  lesion  to  PDT.  The  complete  response
(CR),  partial  response  (PR)  and  discontinued  treatment  (IT).
Also, the  lesions  were  divided  into  subtypes:  superﬁcial  BCC,
BCC nodular  BCC  pigmented.  It  can  be  observed  better  response
to superﬁcial  BCC,  followed  by  CBC  nodular  pigmented  BCC.
Figure  2  Comparison  of  results  obtained  for  the  center  with
photodynamic  experience  in  photodynamic  therapy  (EC)  and
without  previous  experience  (CNE).  Additionally,  the  ﬁgure
shows  the  results  obtained  for  a  subtype  of  lesion  superﬁcial
BCC or  nodular  BCC.
for  the  EC,  showing  the  importance  of  the  previous  edu-
cation  and  experience  of  the  professionals  on  the  therapy.
In  general,  for  BCC  lesions,  a  CR  of  86%  was  observed  at
ECs,  when  compared  to  69.2%  of  the  NECs.  For  sBCC,  was  no
statistically  signiﬁcant  association  between  CR  for  ECs  and
NECs  (85.8%  versus  74.1%)  respectively  (P  =  0.053).  Nodular
lesions  showed  CR  of  90.6%  (39/43),  and  PR  of  6.9%  (3/43)
(P  <  0.01)  for  ECs,  and  NECs  obtained  CR  of  67.5%  (73/108),
and  PR  of  31.4%  (34/108)  (P  <  0.01).
Discussion
This  report  showed  the  preliminary  results  of  a multicenter
clinical  study  that  included  27  dermatological  centers  in  dif-
ferent  regions  of  the  Brazilian  territory.  One  of  the  main  aims
of  this  project  is  to  evaluate  the  proposed  PDT  protocol  in
facilities  of  different  levels,  and  with  medical  professionals
of  distinct  training  and  educational.  A  treatment  technique
for  cancer  to  be  diffusely  implemented  in  Brazil  must  ﬁrst  be
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Figure  3  Response  to  MAL-PDT  in  a  patient  after  two  sessions.  (A)  Untreated  lesion(s)  and  (B)  response  30  days  after  treatment.
Figure  4  (A)  Pigmented  BCC  prior  to  treatment;  (B)  ﬂuorescence  image  of  the  formation  of  PpIX  and  (C)  30  days  after  treatment.
tested  and  show  satisfactory  results  in  all  levels  of  Medicine
services.  In  this  study,  it  was  possible  to  verify  the  inﬂu-
ence  of  the  previous  experience  on  PDT  in  the  treatment
response.  A  CR  was  observed  in  76.5%  of  the  treated  cases
(Fig.  3),  which  is  in  the  range  of  the  rates  reported  in  sci-
entiﬁc  literature,  from  52.2%  to  100%  [2,6—8].  Horn  et  al.
in  2003  observed  that  for  BCC  lesions  a  better  response  was
observed  for  superﬁcial  lesions  when  compared  to  nodular
lesions  (85%  versus  75%)  of  47  and  51  respectively  inves-
tigated  cases  [9].  In  our  study,  sBCC  responded  better  to
PDT  when  compared  to  nodular  lesions,  with  CR  rates  of
80.4%,  74.1%,  respectively  but  it  was  no  statistically  signiﬁ-
cant  (P  =  0.053)  (Fig.  1).  In  BCC,  different  factors  can  affect
the  response  to  the  technique  [10—13].  BCC  lesions  thicker
than  2  mm  present  limited  response  to  topical  PDT  [14],  with
efﬁcacy  decreasing  as  thickness  increased.  In  our  study,  a
limit  of  2  mm  of  thickness  was  set;  however,  in  some  cases,
especially  at  centers  not  specialized  in  Oncology  the  deﬁni-
tion  of  the  lesion  thickness  could  not  be  properly  accessed.
A  limited  penetration  depth  of  MAL  cream  and  of  visible  light
into  the  deeper  layers  of  the  tissue  also  explains  the  resulted
response  rates.  Pigmented  lesions  are  evidently  more  difﬁ-
cult  to  be  treated  with  PDT  due  to  higher  light  absorption
at  the  presence  of  melanin,  preventing  deeper  illumination
with  enough  energy,  resulting  in  lack  of  PDT  response  at
tumor  bottom  margin.
Fig.  4  shows  PpIX  ﬂuorescence  in  the  photosensitized
tissue.  It  is  possible  to  observe  that  the  pigmented  region
absorbs  both  the  excitation  and  the  ﬂuorescence  emission
from  PpIX.  In  the  same  way,  these  absorbing  regions  pro-
duce  shield  effect  during  irradiation,  avoiding  that  all  the
lesion  receive  the  proper  amount  of  light,  reducing  PDT
efﬁcacy  [15].
Pre-PDT  curettage  and/or  debulking  of  nBCC  are  pro-
cedures  proven  to  increase  the  success  of  the  technique.
Christensen  et  al.,  in  2009,  attempted  to  use  curettage
only  to  remove  the  superﬁcial  layers  of  epidermis,  and  have
observed  that  it  contributed  to  high  success  rates  in  their
results  [16].  However,  the  execution  of  these  procedures
depends  on  the  skills  of  the  physician.  In  our  study,  we  have
observed  that  ECs  presented  better  results  when  compared
to  the  NECs.  Even  though,  PDT  is  a simpler  treatment  pro-
cedure  that  requires  less  complex  training,  when  compared
to  surgery,  the  resulted  response  may  derive  from  the  fact
that  an  EC  do  not  require  an  adjustment  period  to  prop-
erly  treat  these  lesions  using  PDT.  This  experience  reﬂects
in  an  improved  selection  of  the  indicated  lesions,  and  also  in
their  ability  in  performing  proper  lesion  curettage  for  PDT.
An  example  of  that  is  that  the  lowest  number  of  nodular  BCC
lesions  was  observed  at  the  ECs.
Conclusion
MAL-PDT  is  a  noninvasive,  safe,  moderately  effective,  and
well-tolerated  option  for  treating  superﬁcial  BCC  lesion.
Moreover,  we  can  anticipate  that  the  BCC  subtype  and  med-
ical  experience  inﬂuence  the  ﬁnal  result.  The  fact  that  the
lack  of  previous  knowledge  on  PDT  results  in  a  lower  degree
of  success,  indicates  that  a  closer  interaction  of  the  pro-
fessionals  involved  in  the  multicenter  study  should  provide
an  improved  education  on  the  PDT  principles  and  clinical
case  discussions.  As  the  study  progress,  we  expected  that
the  acquire  experience  will  improve  considerable  outcome
results.
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